BioSpace News Archive

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 353 owned and/or operated outpatient imaging centers, reported financial results for its second quarter of 2021.

Aravive Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced the Company has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma.

Eagle Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2021.

BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, provided an update on its corporate progress and reported financial results for the second quarter and first half-year ended June 30, 2021.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration.

Technologies for screening donated blood for infectious such as HIV1, HIV2, HBV, and HCV play a crucial role in deciding the safety of transfusions.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global wireless portable medical devices market is anticipated to grow at 11% CAGR between 2021 and 2031 to reach valuation of US$ 33 Bn by 2031.The market was valued at US$ 15 Bn in 2020.

Calliditas Therapeutics AB announced that the U.S. Food and Drug Administration has granted Fast Track Designation for its lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis.